Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase

[1]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  C. Boshoff,et al.  Toward personalized treatment approaches for non-small-cell lung cancer , 2021, Nature Medicine.

[3]  E. Petricoin,et al.  IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK , 2021, Scientific Reports.

[4]  R. Deng,et al.  CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression , 2021, Autophagy.

[5]  Baofeng Yu,et al.  Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug. , 2021, Acta biochimica et biophysica Sinica.

[6]  J. Hurley,et al.  Autophagosome biogenesis comes out of the black box , 2021, Nature Cell Biology.

[7]  Huanchun Chen,et al.  Selective autophagy receptor SQSTM1/ p62 inhibits Seneca Valley virus replication by targeting viral VP1 and VP3 , 2021, Autophagy.

[8]  Jeffrey W. Clark,et al.  Crizotinib in Patients With MET-Amplified NSCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  T. Ikezoe,et al.  Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib , 2021, International Journal of Hematology.

[10]  J. Bonifacino,et al.  The ubiquitin isopeptidase USP10 deubiquitinates LC3B to increase LC3B levels and autophagic activity , 2021, The Journal of biological chemistry.

[11]  J. Encinar,et al.  Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines , 2020, Cancers.

[12]  G. Dianov,et al.  A unified model for the G1/S cell cycle transition , 2020, Nucleic acids research.

[13]  Zhaoxia Wang,et al.  Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1 , 2020, Cell Death & Disease.

[14]  Q. Mo,et al.  Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer , 2020, Breast Cancer Research and Treatment.

[15]  Yurong Song,et al.  PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers , 2020, Cell Death & Disease.

[16]  R. Bianco,et al.  c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve? , 2020, Cancers.

[17]  F. Forouzandeh,et al.  SQSTM1/p62 and PPARGC1A/PGC-1alpha at the interface of autophagy and vascular senescence , 2020, Autophagy.

[18]  Cheng-Ta Yang,et al.  The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC) , 2020, Cancers.

[19]  Lei Liu,et al.  Thyroid hormone mediates cardioprotection against postinfarction remodeling and dysfunction through the IGF-1/PI3K/AKT signaling pathway. , 2020, Life sciences.

[20]  N. Howlett,et al.  Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells , 2020, Cancers.

[21]  M. Malumbres,et al.  Mammalian cell cycle cyclins. , 2020, Seminars in cell & developmental biology.

[22]  M. Barbacid,et al.  Targeting the MAPK Pathway in KRAS-Driven Tumors. , 2020, Cancer cell.

[23]  G. Juhász,et al.  Autophagosome-lysosome fusion. , 2020, Journal of molecular biology.

[24]  H. Reikvam,et al.  The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells , 2020, International journal of molecular sciences.

[25]  Peter T. Harrison,et al.  Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer , 2020, Seminars in cancer biology.

[26]  C. D. Dela Cruz,et al.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention. , 2020, Clinics in chest medicine.

[27]  Tao Yang,et al.  Biphasic Mathematical Model of Cell–Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells , 2020, Cancers.

[28]  W. Kolch,et al.  Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity , 2020, International journal of molecular sciences.

[29]  A. Tan.  Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) , 2020, Thoracic cancer.

[30]  I. Gukovsky,et al.  Transgenic expression of GFP-LC3 perturbs autophagy in exocrine pancreas and acute pancreatitis responses in mice , 2020, Autophagy.

[31]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[32]  Kuang-Tai Kuo,et al.  Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[33]  Tao Yang,et al.  Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells , 2019, Molecules.

[34]  Yu Wu,et al.  Sirtuin 6 overexpression relieves sepsis-induced acute kidney injury by promoting autophagy , 2019, Cell cycle.

[35]  R. Amaravadi,et al.  Targeting autophagy in cancer , 2018, Cancer.

[36]  H. Varmus,et al.  YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics , 2018, Proceedings of the National Academy of Sciences.

[37]  M. Sheetz,et al.  EGFR family and Src family kinase interactions: mechanics matters? , 2018, Current opinion in cell biology.

[38]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[39]  R. Moorehead,et al.  BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549 , 2016, BMC Research Notes.

[40]  Michael Thomas,et al.  Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. , 2014, Human pathology.

[41]  L. Skoog,et al.  Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit , 2012, Breast Cancer Research and Treatment.

[42]  Roderich E. Schwarz,et al.  BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer , 2012, Molecular Cancer Therapeutics.

[43]  K. Siddle.  Signalling by insulin and IGF receptors: supporting acts and new players. , 2011, Journal of molecular endocrinology.

[44]  Min-jian Kong,et al.  Down‐regulation of IGF‐IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice , 2007, Cell biology international.